May 15, 2024 · Tizona Therapeutics is developing cancer treatments that have the potential to be first- and best-in-class treatments, and core components of immunotherapy combination regimens.

Our oncology pipeline is focused on restoring and bolstering immune responses. Tizona is enrolling patients in two randomized arms within the ongoing Phase 1b clinical trial (NCT04485013) to evaluate either TTX-080 plus cetuximab and FOLFIRI or cetuximab and FOLFIRI alone in biomarker-defined metastatic colorectal cancer.

Tizona Therapeutics is applying novel scientific insights to change the course of cancer progression and relapse.

Christine O’Brien is the Chief Executive Officer for Tizona and a member of the Board of Directors. O’Brien joined Tizona in 2015 and served most recently as the Chief Operating Officer.

Jul 21, 2020 · Tizona equity holders will be eligible to receive up to $1.25 billion in an option exercise fee and potential future milestone payments. Gilead will also provide funding to support Tizona’s ongoing research and development to advance its novel pipeline.

Here at Tizona Therapeutics, we value Patients First! With this goal in mind, Tizona develops next-generation immunotherapies. Join us today.

May 23, 2024 · Tizona translates scientific breakthroughs into therapeutics that stimulate the immune system and counter immune suppression. Tizona’s pipeline includes TTX-080 , which targets HLA-G and is being evaluated in a Phase 1b clinical study in advanced cancers.

Table 6. Treatment-Related Adverse Events of TTX-080 + Cetuximab in mHNSCC Patients TRAE reported in ≥5% of patients Grade 1 Grade 2 Grade 3 Grade 4 Total (N=23)

Tizona Therapeutics, Inc. is located at 4000 Shoreline Court, Suite 200 South San Francisco, CA 94080

Tizona Therapeutics Announces Expansion of Phase 1b Clinical Trial to Evaluate TTX-080 in Combination with EGFR Inhibitor Cetuximab and Chemotherapy in Advanced Colorectal Cancer. May 23, 2024 Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024. 2021